Moderna, Inc. — Director's Dealing 2020

Feb 27, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-02-25

Reporting Person: Kim Lorence H. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-25	Common Stock	S	1248	$25.59	Disposed	1301262	Direct
2020-02-25	Common Stock	S	100	$26.14	Disposed	1301162	Direct
2020-02-26	Common Stock	S	5088	$27.96	Disposed	1296074	Direct
2020-02-26	Common Stock	S	12819	$28.79	Disposed	1283255	Direct
2020-02-26	Common Stock	S	745	$29.46	Disposed	1282510	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $26.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.42 to $29.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.